Apogee Therapeutics (APGE) Other Non-Current Liabilities (2022 - 2026)

Apogee Therapeutics (APGE) has reported Other Non-Current Liabilities for 5 consecutive years, with $600000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $600000.0; the TTM figure through Mar 2026 stood at $600000.0 (changed N/A YoY), while the FY2025 annual figure was $2.1 million, up 2000.0% from the prior year.
• Other Non-Current Liabilities declined to $600000.0 in Q1 2026 per APGE's latest filing, from $2.1 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $8.0 million in Q4 2022 and bottomed at $100000.0 in Q4 2024.
• Historically, Other Non-Current Liabilities has averaged $3.0 million across 5 years, with a median of $2.1 million in 2025.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities plunged 98.08% — and 2025, when it jumped 2000.0%.
• Apogee Therapeutics' Other Non-Current Liabilities stood at $8.0 million in 2022, then plunged by 35.0% to $5.2 million in 2023, then slumped by 98.08% to $100000.0 in 2024, then surged by 2000.0% to $2.1 million in 2025, then sank by 71.43% to $600000.0 in 2026.
• Business Quant data shows APGE's Other Non-Current Liabilities at $600000.0 in Q1 2026, $2.1 million in Q4 2025, and $100000.0 in Q2 2025.